But moving into 2023, watch out for these five financial and corporate outlooks that may roil the industry in the next 12 to 24 months. Life sciences-heavy marketsAfter a record-breaking 2021, deal flow and deal values are down in 2022. In a January to June six-month period in 2021 and 2022, deal flow value is down $61 billion this year, and the number of deals has fallen from 204 to 137,
While the R&D work may show promise, without the money, these companies will open themselves up to be gobbled up by the likes of a Bristol-Myers, a GSK or a Pfizer.Big Pharma will soon be on a hunt to replenish some $200 billion of revenue from drugs that are coming off patents in the next five years.
Two years after the pandemic started, more than 7,000 clinical trials had been initiated related to Covid-19 in the National Institutes of Health clinical trials database, Deloitte’s report noted.